Skip to search formSkip to main contentSkip to account menu

Biphasic 12 HR Hyoscyamine Sulfate 0.375 MG Extended Release Oral Tablet

Known as: hyoscyamine sulfate 0.375 MG Biphasic 12HR Extended Release Oral Tablet, HYOSCYAMINE 0.125MG IR/0.25MG TAB,SA [VA Product], hyoscyamine sulfate 0.375 MG Biphasic (0.125 MG / 0.25 MG) 12 HR Extended Release Oral Tablet 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Introduction: Many patients with implantable cardioverter defibrillators (ICDs) have older lead systems, which are usually not… 
1996
1996
BACKGROUND The purpose of this study was to prospectively analyze redetection problems after unsuccessful shock with different… 
1996
1996
Electrode polarity has been reported to be one of the factors that affect defibrillation efficacy. We studied the influence of… 
Review
1994
Review
1994
ICD for Treatment of AF. The experience gained using intracardiac cardioverter defibrillators for the treatment of ventricular… 
Highly Cited
1991
Highly Cited
1991
Recent studies suggest that 1) electrically induced fibrillation and defibrillation involve prolongation of refractoriness by the… 
1991
1991
The estimation of arterial carbon dioxide pressure (Paco2) by Professor J Jordanoglou and colleagues (July 1990;45:520-4) assumes…